

March 28, 2024

Kiran Asarpota
Chief Operating Officer
ASLAN Pharmaceuticals Ltd
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190

Pharmaceuticals Ltd
Statement on Form F-3
2024

Re: ASLAN
Registration
Filed March 25,
File No. 333-278217

Dear Kiran Asarpota:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

McNamara at 202-551-7349 with any questions.

Please contact Jimmy

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Carlos Ramirez